New Product Launches Along with Rising Global Prevalence of Chronic Sinusitis is Propelling the Growth of Global Nasal Polyposis Drug Market

The global nasal polyposis drug market is anticipated to grow at a significant CAGR of 6.5% during the forecast period 2022-2028. The rising frequency of different malignancies and immunological illnesses, and the growing global elderly population, are two main factors driving the market's growth. Moreover, the rise in government initiatives along with new product launches by major players in the industry is propelling the growth of the market. For instance, in August 2021, Medtronic PLC announced that it had entered into a definitive agreement with Intersect ENT Inc. in which Medtronic will acquire it for approximately $1.1 billion. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and customer base will enhance Medtronic's efforts to have a positive impact on patients who suffer from chronic rhinosinusitis (CRS). Further, in December 2020, Novartis AG announced that the US Food and Drug Administration (FDA) had approved the company's supplemental Biologics License Application (sBLA) for Xolair for the add-on maintenance treatment of nasal polyps in adults patients 18 years of age and older with inadequate response to nasal corticosteroids. With this approval, Xolair is now the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation.

Browse the full report of "Global Nasal Polyposis Drug Market Size, Share, and Trends Analysis Report By Drug Class (Corticosteroids, Antibiotics, Leukotriene Inhibitors, and Others) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028" at https://www.omrglobal.com/industry-reports/nasal-polyposis-drug-market

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Distribution Channel 

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape - including, GlaxoSmithKline PLC, Sanofi SA, Merck & Co. Inc., OptiNose US Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Nasal Polyposis Drug Market Report Segment

By Drug Class

• Corticosteroids
• Antibiotics
• Leukotriene Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Nasal Polyposis Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa